Hims & Hers Health, Inc. (HIMS)
Automate Your Wheel Strategy on HIMS
With Tiblio's Option Bot, you can configure your own wheel strategy including HIMS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HIMS
- Rev/Share 8.038
- Book/Share 2.4743
- PB 22.1197
- Debt/Equity 0.1154
- CurrentRatio 1.5942
- ROIC 0.2452
- MktCap 11791797420.0
- FreeCF/Share 1.0821
- PFCF 49.0881
- PE 73.9042
- Debt/Assets 0.0711
- DivYield 0
- ROE 0.3597
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Reiterated | HIMS | Needham | -- | Buy | $61 | $65 | June 4, 2025 |
| Downgrade | HIMS | TD Cowen | Buy | Hold | -- | $30 | April 29, 2025 |
| Downgrade | HIMS | Morgan Stanley | Overweight | Equal Weight | $42 | $60 | Feb. 18, 2025 |
| Downgrade | HIMS | Citigroup | Neutral | Sell | $24 | $25 | Jan. 10, 2025 |
| Initiation | HIMS | BTIG Research | -- | Buy | -- | $35 | Jan. 7, 2025 |
| Initiation | HIMS | Morgan Stanley | -- | Overweight | -- | $42 | Dec. 17, 2024 |
| Initiation | HIMS | Needham | -- | Buy | -- | $24 | Aug. 22, 2024 |
News
Hims & Hers: Revolutionizing Healthcare
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Positive
The company's vertically integrated platform enhances scalability and efficiency, controlling the entire patient experience from consultation to medication delivery. Partnerships, especially with Novo Nordisk for GLP-1 weight-loss drugs, significantly boost revenue and deepen customer relationships. Embracing AI and peptide therapies positions Hims & Hers for future growth, though regulatory compliance and reliance on third-party suppliers pose risks.
Read More
4 MedTech Stocks Poised to Outshine Q1 Earnings Estimates
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
MedTech companies' quarterly results are likely to reflect base business recovery on a year-over-year basis. Let's see how HIMS, GMED, QDRL and HAE are poised ahead of their earnings release.
Read More
Hims & Hers vs. Teladoc: Which Telehealth Stock Is the Better Buy Now?
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Both HIMS and TDOC are technology-intensive healthcare companies that leverage their strengths in the digital health space to enhance their platforms. Which one is a better investment?
Read More
Hims & Hers Stock Soars on Novo Nordisk Collaboration
Published: April 30, 2025 by: MarketBeat
Sentiment: Positive
Every once in a while, investors come across some of the best names in a given industry, which then become subject to the best news and developments during a holding period. Today's best pick seems to be in the medical sector.
Read More
Hims & Hers stock price soars after partnership with Novo Nordisk to offer weight-loss drug Wegovy
Published: April 30, 2025 by: Fast Company
Sentiment: Positive
Shares in Hims & Hers Health, Inc. (NYSE: HIMS) are skyrocketing in early-morning trading today after the telehealth company announced a new partnership with the Danish pharmaceutical giant Novo Nordisk. That partnership will see Hims & Hers offer Novo Nordisk's weight-loss drug Wegovy through its platform.
Read More
Hims & Hers Health (HIMS) Stock Jumps 23.0%: Will It Continue to Soar?
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers Health (HIMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Read More
Hims & Hers Health: GLP-1 Deals De-Risk The Story
Published: April 29, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health partners with Novo Nordisk to offer Wegovy, de-risking investment but not significantly altering the business focus on personalized healthcare solutions. The health and wellness platform already targeted $725 million in weight-loss sales this year, without including any branded GLP-1 sales. The company's core business remains robust, with significant contributions from sexual health, dermatology, and mental health, accounting for over $1.2 billion in 2024 sales.
Read More
Why Hims & Hers Health and LifeMD Are Skyrocketing Today
Published: April 29, 2025 by: The Motley Fool
Sentiment: Positive
Shares of Hims & Hers Health (HIMS 25.46%) and LifeMD (LFMD 35.41%) are surging on Tuesday. The companie' stocks had jumped 24% and 34%, respectively, as of 3:15 p.m.
Read More
Hims & Hers stock pops on Novo Nordisk partnership
Published: April 29, 2025 by: Proactive Investors
Sentiment: Positive
Hims & Hers (NYSE:HIMS) shares surged after it announced a partnership with Novo Nordisk that will allow it to offer the drugmaker's weight loss product Wegovy through its telehealth platform. Investors welcomed the collaboration, which positions Hims & Hers to participate directly in the fast-growing market for GLP-1 weight-loss drugs.
Read More
Hims & Hers Stock Surges As It Collaborates With Novo Nordisk To Sell Weight Loss Drug Wegovy On Its Platform
Published: April 29, 2025 by: Benzinga
Sentiment: Positive
Novo Nordisk A/S NVO and Hims & Hers Health, Inc. HIMS announced a long-term collaboration on Tuesday.
Read More
Hims & Hers partners with Novo Nordisk to sell Wegovy
Published: April 29, 2025 by: Fox Business
Sentiment: Positive
Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on its telehealth platform.
Read More
Wegovy Today, Ozempic Tomorrow: Partnership With Novo Is Hims & Hers Comeback
Published: April 29, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health, Inc. just announced a partnership with Novo Nordisk, Ro and LifeMD to sell their Wegovy at a discounted price. The deal is a game changer, enabling Hims to offer Wegovy at $599/month versus $1,999/month. I think this deal hints at potential to do the same with Ozempic further boosting the stock, which is already up +30% in pre-market trading.
Read More
White House Slams AMZN, HIMS & NVO Wegovy Partnership, SOFI Rallies
Published: April 29, 2025 by: Schwab Network
Sentiment: Negative
Amazon (AMZN) shares faced selling pressure after the White House called the company's decision to display tariff costs on products a "hostile and political act." Diane King Hall notes it's just the latest company following a formula.
Read More
HIMS stock spikes over 40%; Time to buy?
Published: April 29, 2025 by: Finbold
Sentiment: Positive
Summary ⚈ HIMS stock surged up to 45% after announcing a partnership with Novo Nordisk to offer Wegovy through its platform.⚈ The move positions Hims & Hers to capitalize on booming demand for weight-loss medications.
Read More
Hims & Hers to Sell Novo Nordisk's Wegovy in U.S., Shares Soar
Published: April 29, 2025 by: WSJ
Sentiment: Positive
Him & Hers Health and Novo Nordisk are collaborating to offer weight-loss treatment, including access to Wegovy along with other services to treat obesity.
Read More
Bet on Winning DuPont Analysis & Pick 3 Top Stocks
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Do you have more faith in DuPont analysis than simple ROE calculation? Tap EverQuote (EVER), Hims & Hers Health (HIMS) and Sprouts Farmers Market (SFM).
Read More
Hims & Hers' stock rockets after teaming up with its rival Wegovy maker
Published: April 29, 2025 by: Market Watch
Sentiment: Positive
Health and wellness company Hims & Hers, which sells alternatives to weight-loss drugs like Wegovy, is now collaborating with the maker of Wegovy.
Read More
Hims & Hers and Novo Nordisk Team Up to Expand Affordable Access to Care
Published: April 29, 2025 by: Business Wire
Sentiment: Neutral
SAN FRANCISCO--(BUSINESS WIRE)--Novo Nordisk and Hims & Hers Health, Inc. (NYSE: HIMS) today announced a long-term collaboration designed to make proven obesity care and treatments more accessible, more affordable, and more connected for millions of Americans. As a first step, Americans can now access NovoCare® Pharmacy directly through the Hims & Hers platform, with a bundled offering of all dose strengths of Wegovy® and a Hims & Hers membership, which includes access to 24/7 care,.
Read More
Hims & Hers: Look Past Near-Term GLP-1 Risks, This Is A Great Dip To Buy
Published: April 23, 2025 by: Seeking Alpha
Sentiment: Neutral
Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business, presenting a buying opportunity for long-term investors. The company is ramping up liraglutide manufacturing (an alternative to semaglutide) which will be able to recoup lost sales in its weight loss division after the FDA shortage of semaglutide ends. Hims trades at an appealing 18.1x EV/FY26 adjusted EBITDA, which is modest for a company growing revenue and adjusted EBITDA at a >60% y/y pace.
Read More
Hims & Hers: Top Pick For The Next Decade
Published: April 21, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers has shown explosive growth, with potential revenue of $2.5B in FY25, trading at a low 2.4x FY25 sales. Despite the high short interest and bear arguments, HIMS' data-driven personalization and high CAC are strategic for long-term disruption in healthcare. HIMS boasts $209M in free cash flow, a 14% FCF margin, and positive net income, making it a financially robust small-cap company.
Read More
3 Medical Info Systems Stocks to Ride the AI Wave in Trump Tariff Era
Published: April 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks Medical Info Systems industry stocks like VEEV, HIMS and BFLY are expected to gain from the Stargate Project and provide relief amid tariff tension.
Read More
3 Undervalued Medical Device Stocks to Buy in 2025 Amid Tariff Woes
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Here, we discuss three medical device stocks ,COR, HIMS and PBH, that offer cheap valuations, making them attractive bets amid tariff risks.
Read More
Hims & Hers Stock Gains 5.8% in 3 Months: Here's How to Play it
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
HIMS is enhancing offerings and expanding its health and wellness products and services to solidify its footing. However, macro challenges are likely to hurt its performance.
Read More
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
3 Stocks to Buy for "Liberation" From Trump Tariffs & Recession Woes
Published: April 02, 2025 by: Zacks Investment Research
Sentiment: Neutral
In 2025, companies like MASI, BSX and HIMS are expected to overcome challenges and sustain strong growth and market leadership.
Read More
Hims Stock Rockets After Inking Deal To Sell Eli Lilly's Obesity Drug, Zepbound
Published: April 01, 2025 by: Investors Business Daily
Sentiment: Positive
Hims stock surged Tuesday after the compounding pharmacy said it would sell Eli Lilly's branded weight-loss drug on its telehealth platform. The post Hims Stock Rockets After Inking Deal To Sell Eli Lilly's Obesity Drug, Zepbound appeared first on Investor's Business Daily.
Read More
Hims & Hers to sell Lilly's Zepbound on its telehealth platform
Published: April 01, 2025 by: Reuters
Sentiment: Positive
Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lilly's weight-loss drug Zepbound on its platform.
Read More
Here's why Hims & Hers stock price has crashed: buy the dip?
Published: March 27, 2025 by: Invezz
Sentiment: Negative
Hims & Hers stock price has imploded this year, erasing some of the gains made in 2024 when it became one of the top-performing companies in the US. HIMS has crashed to $33.35, down by over 54% from its highest point this year.
Read More
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Published: March 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Jumping Into The FDA Gamble: Initiating Hims & Hers With A Buy
Published: March 20, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health, Inc. stock surged to $68, and the subsequent 50% crash is the talk of the town. I'm eyeing it as a favorable high-risk, high-reward play. HIMS stock plummeted after the FDA halted approval of its top-selling GLP-1 weight loss drug, which is priced at $165 and offers the same as Ozempic, priced on average $1,000. The FDA's pending decision on semaglutide's shortage status, due April 22nd, is crucial; a favorable ruling could boost HIMS stock significantly.
Read More
About Hims & Hers Health, Inc. (HIMS)
- IPO Date 2019-09-13
- Website https://www.forhims.com
- Industry Household & Personal Products
- CEO Mr. Andrew Dudum
- Employees 1637